Overview
- Reuters reported Friday that HHS officials explored whether some SSRI antidepressants could face restrictions, and spokesman Andrew Nixon then said the department had not discussed bans.
- Kennedy on Monday unveiled steps to reduce reliance on SSRIs, including new reimbursement guidance for tapering care, expanded training for clinicians, and public reporting on prescribing trends.
- Regulatory experts said the FDA cannot unilaterally pull long‑approved drugs without new safety evidence or proof of fraud in the original approval, and any review would take months or years.
- The American Psychiatric Association backed more research on prescribing and safe discontinuation but rejected claims that overprescribing is the main cause of the mental health crisis.
- About one in six U.S. adults now take SSRIs, so any policy shift could affect treatment plans, even as Kennedy told patients he is not asking them to stop their medication.